The partnership will expand Charles River’s biologics testing capabilities geographically and help to accommodate demand for biologics therapeutics, especially cell and gene therapies, reaffirming the company’s commitment as a global development partner.
This strategic relationship will also enable JADE to expand their current global Good Manufacturing Practice (GMP) product testing operations in Shanghai into a second facility and further build upon its current offering of comprehensive biologics quality management and testing services.
“Working with JADE, we will be able to combine our expertise to provide localized knowledge with a deep scientific and regulatory network, positioning both organizations as go-to partners for clients in this competitive market,” said Birgit Girshick, corporate executive vice president, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian.
As the biologics therapeutics industry across the globe continues to grow at a rapid pace, so does the demand for a reliable contract services partner. The recent growth in commercialization efforts in the cell and gene therapy market requires both scientific and regulatory expertise to navigate the complex, global regulatory environment.
JADE’s deep understanding of global trends and the local environment, and its infrastructure designed to support clients of all sizes—from local start-ups to global organizations—makes it a valuable addition to Charles River’s network. The addition of a second testing facility, which will come online later this year, will provide additional capacity to better support clients’ growing needs. The new facility will offer GMP and Good Laboratory Practice (GLP) services to clients.